Lyell Immunopharma Inc
NASDAQ:LYEL
Cash Flow Statement
Cash Flow Statement
Lyell Immunopharma Inc
| Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | |||||||||||||||||||||
| Net Income |
(204)
|
(230)
|
(192)
|
(205)
|
(250)
|
(263)
|
(237)
|
(258)
|
(183)
|
(182)
|
(210)
|
(190)
|
(235)
|
(228)
|
(210)
|
(204)
|
(343)
|
(335)
|
(331)
|
(326)
|
|
| Depreciation & Amortization |
4
|
5
|
8
|
11
|
14
|
16
|
17
|
18
|
18
|
19
|
20
|
20
|
20
|
20
|
20
|
20
|
20
|
18
|
16
|
14
|
|
| Stock-Based Compensation |
33
|
43
|
51
|
65
|
62
|
72
|
79
|
85
|
82
|
74
|
66
|
57
|
47
|
42
|
36
|
34
|
33
|
30
|
27
|
24
|
|
| Other Non-Cash Items |
40
|
58
|
72
|
73
|
106
|
101
|
100
|
113
|
78
|
79
|
69
|
48
|
47
|
44
|
32
|
30
|
164
|
151
|
153
|
157
|
|
| Change in Working Capital |
(0)
|
(5)
|
(3)
|
3
|
4
|
6
|
(31)
|
(35)
|
(82)
|
(84)
|
(42)
|
(42)
|
3
|
4
|
(0)
|
(1)
|
(3)
|
(9)
|
(9)
|
(11)
|
|
| Cash from Operating Activities |
(161)
N/A
|
(171)
-6%
|
(116)
+32%
|
(120)
-3%
|
(126)
-5%
|
(141)
-11%
|
(151)
-7%
|
(163)
-8%
|
(170)
-4%
|
(168)
+1%
|
(163)
+3%
|
(163)
0%
|
(164)
0%
|
(160)
+3%
|
(158)
+1%
|
(156)
+2%
|
(162)
-4%
|
(175)
-8%
|
(171)
+2%
|
(165)
+4%
|
|
| Investing Cash Flow | |||||||||||||||||||||
| Capital Expenditures |
(51)
|
(64)
|
(81)
|
(80)
|
(66)
|
(56)
|
(39)
|
(30)
|
(24)
|
(16)
|
(10)
|
(7)
|
(3)
|
(1)
|
(1)
|
(0)
|
(32)
|
(32)
|
(32)
|
(32)
|
|
| Other Items |
(222)
|
43
|
121
|
65
|
(56)
|
(228)
|
(181)
|
(102)
|
13
|
63
|
184
|
339
|
187
|
175
|
67
|
(31)
|
154
|
202
|
169
|
171
|
|
| Cash from Investing Activities |
(274)
N/A
|
(21)
+92%
|
40
N/A
|
(15)
N/A
|
(122)
-693%
|
(284)
-134%
|
(220)
+23%
|
(132)
+40%
|
(12)
+91%
|
47
N/A
|
175
+274%
|
331
+90%
|
184
-44%
|
174
-6%
|
66
-62%
|
(32)
N/A
|
122
N/A
|
170
+39%
|
138
-19%
|
139
+1%
|
|
| Financing Cash Flow | |||||||||||||||||||||
| Net Issuance of Common Stock |
477
|
1
|
395
|
394
|
401
|
403
|
12
|
18
|
11
|
9
|
7
|
2
|
2
|
2
|
2
|
2
|
1
|
1
|
1
|
51
|
|
| Other |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(1)
|
(1)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
|
| Cash from Financing Activities |
477
N/A
|
1
-100%
|
395
+31 480%
|
394
0%
|
401
+2%
|
403
+0%
|
12
-97%
|
17
+45%
|
11
-38%
|
8
-25%
|
7
-16%
|
2
-73%
|
2
-6%
|
2
+6%
|
2
-18%
|
2
+10%
|
1
-20%
|
1
-2%
|
1
-52%
|
51
+8 052%
|
|
| Change in Cash | |||||||||||||||||||||
| Net Change in Cash |
42
N/A
|
(190)
N/A
|
318
N/A
|
259
-19%
|
153
-41%
|
(22)
N/A
|
(359)
-1 535%
|
(277)
+23%
|
(170)
+39%
|
(113)
+34%
|
19
N/A
|
170
+811%
|
22
-87%
|
16
-27%
|
(91)
N/A
|
(186)
-104%
|
(39)
+79%
|
(4)
+90%
|
(33)
-750%
|
25
N/A
|
|
| Free Cash Flow | |||||||||||||||||||||
| Free Cash Flow |
(212)
N/A
|
(235)
-11%
|
(197)
+16%
|
(200)
-1%
|
(192)
+4%
|
(197)
-2%
|
(190)
+4%
|
(192)
-1%
|
(194)
-1%
|
(184)
+5%
|
(173)
+6%
|
(171)
+1%
|
(166)
+2%
|
(161)
+3%
|
(159)
+1%
|
(156)
+2%
|
(194)
-24%
|
(207)
-7%
|
(203)
+2%
|
(197)
+3%
|
|